AION Labs is a first-of-its-kind venture studio formed by leading global pharma companies, technology giants, and top-tier investors. AION Labs mission is to create and adopt AI technologies that will transform the process of drug discovery and development for the betterment of human health. AION Labs partners include AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by BioMed X and the Israeli Innovation Authority. Based in Rehovot, near the Weizmann Institute of Science, at the heart of Israel’s vibrant biotech ecosystem. AION Labs fosters innovation through a unique venture studio model, creating startups that bridge global pharmaceutical expertise with advanced AI and biotechnology. Their venture studio model reduces risk by facilitating cross-industry partnerships, enabling seamless data sharing, and offering unparalleled access to pharma R&D expertise. This allows startups to fast-track their path to market, enabling them to create and validate transformative solutions for the biotech industry. AION Labs’ company creation process, through both the AION Building and AION Seeding tracks, addresses unmet industry needs through a rigorous validation process. Both tracks provide funding and unparalleled access to pharma R&D expertise, differing in development stages and technology maturity.